Sol-Gel Technologies Ltd.
No enriched coverage for $SLGL in the last 7 days.
Sol-Gel Technologies Ltd. (SLGL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 • So
Opaleye Management Inc. purchased 951 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at $71.50 on 2026-08-12.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Recent SLGL coverage spans insider activity, financial news and earnings.
In the last 30 days, SLGL insiders filed 1 SEC Form 4 transaction — 1 purchase ($68K) and no sales. The most active reporter was Opaleye Management Inc. with 1 filing.
Quarterly revenue collapse and trial progress may pressure the stock short‑term, but continued Phase 3 data could support upside.
This is an insider-style ownership increase, but it is indirect and small, with no 10b5-1 plan disclosed.
A defined Phase 3 topline window helps traders map catalysts and manage event risk.
This is an insider/affiliate open-market purchase with no 10b5-1 plan, but it is small relative to typical institutional flows.
This is a routine insider Form 4 purchase with modest size and no 10b5-1 plan, but it is unlikely to drive near-term price by itself.
alphai scores every news story that mentions SLGL with an AI model for sentiment and relevance, and aggregates insider trades from Sol-Gel Technologies Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sol-Gel Technologies Ltd. (SLGL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 • So
2 min readOpaleye Management Inc. purchased 951 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at $71.50 on 2026-08-12.
2 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readOpaleye Management Inc. purchased 1,695 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.64 ($73.43–$73.89, $0.12M total) across 2 trades over 2026-07-13 to 2026-07-14.
2 min readOpaleye Management Inc. purchased 529 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.80 ($73.69–$73.95) across 2 trades over 2026-07-08 to 2026-07-10.
2 min readOpaleye Management Inc. purchased 1,712 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $71.97 ($71.97–$71.99, $0.12M total) across 2 trades over 2026-07-01 to 2026-07-02.
3 min readGreat Point Partners, LLC, Dr. Jeffrey R. Jay, and Ms. Lillian Nordahl have disclosed an 8.45% beneficial ownership stake in Sol-Gel Technologies Ltd. (SLGL). This stake, totaling 274,363 ordinary shares, is reported in a Schedule 13G filing. The percentage is based on 3,245,270 shares outstanding as of March 24, 2026, and the reporting persons share voting and dispositive power over these shares, which are held by funds managed by Great Point.
3 min read• Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed.
3 min readNESS ZIONA, Israel, May 23, 2025 ( GLOBE NEWSWIRE ) -- Sol-Gel Technologies, Ltd. ( NASDAQ: SLGL ) , a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025
2 min read